SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

A strong quarterly earnings beat and upbeat guidance have driven attention, with traders highlighting improving growth, cash flow, and a potential ad-tech re-rating. The bullish reaction is tempered by debate over profit-taking, options-related volatility, short pressure, and whether the post-earnings rally can hold.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

A sharp AVAX rebound and technical breakout, including a move back above the 200-day moving average, has drawn attention amid broader altcoin strength. Traders are divided between bullish calls for continued momentum and skepticism that the move will hold, citing weak volume, repeated selloffs, and token-inflation concerns.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes CEO transition is driving attention after the company reported a strong quarterly update and raised its outlook, with traders debating whether a new leader can accelerate its ADAS, robotaxi and robotics strategy. The community is also focused on the pace of the authorized share buyback, with bulls viewing it as valuation support while skeptics cite leadership uncertainty and continued selling pressure.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutuss modified Dutch-auction tender offer is driving attention, with traders debating whether to tender shares or hold for potential value from a reduced share count and future litigation or HepB catalysts. Some view the offer as a valuation floor and short-covering setup, while others worry it could suppress the stock and strengthen Roivants position at shareholders expense.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

A reported Bonk DAO exploit and related exchange-delisting concerns are driving attention, with traders linking the security incident to BONKs sharp selloff and questioning whether the team will resolve the flaw. Some participants are buying the dip and expecting a recovery if a fix arrives or broader Solana and meme-coin momentum returns, while others view the token as highly risky or potentially headed lower.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Kylian Mbapps departure from Nike for On is fueling concern that the brand is losing high-profile athletes and market share in soccer, though some traders view the exit as a cost-saving move involving an overrated endorser. The debate is occurring alongside broader worries about Nikes weak growth, management, competition and persistent share-price declines.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Speculation around a potential CRO ETF and related regulatory developments is driving attention, with traders debating repeated approval delays rather than citing a confirmed launch. The community remains divided, as bullish expectations for an ETF, a new Cronos app and institutional interest compete with concerns about token emissions, past unburned supply and persistent selling pressure.

Grayscale Investments LLC - Grayscale Zcash ETF

Grayscale Zcash Trust ZEC

Grayscales planned 3-for-1 forward split is the primary catalyst, with traders viewing the lower post-split share price and improved accessibility as supportive for liquidity and demand amid Zcashs rally. The community is broadly bullish, though some traders debate ZCSHs lag versus ZEC and its premium or discount to net asset value.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Auvelitys launch for Alzheimers-related agitation and rising new-prescription trends are driving attention, reinforced by favorable analyst commentary and recent healthcare conferences. Traders remain divided, with bulls citing accelerating uptake and possible undercounting from samples and long-term-care channels, while others point to flat or uneven weekly prescriptions, low-volume selling, and broader biotech-sector pressure.

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

The Hunter Biden-themed memecoin is drawing attention after an extremely volatile launch followed by an almost 99% collapse, with traders broadly labeling it a rug pull or scam and questioning its utility. A smaller group is buying the dip or betting on a speculative squeeze, while debate focuses on thin liquidity, token allocations, and whether the crash reflects a technical issue or deliberate selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 15th

BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? 

Equity

The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology. 


Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?

Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright...

Heron Therapeutics Q1 Earnings Call Highlights

Heron Therapeutics Q1 Earnings Call Highlights...

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -33.33% and -3.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of +242.86% and +44.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

Heron Therapeutics Inc

Extremely Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.3097
Prev Close	$0.3157
Open	$0.3162
Dividend Yield	0.00%
50-Day Moving Average	$0.386
Beta	1.42
Avg. Volume	3.11M
PE Ratio	-1.63

52-Week High	$1.58
52-Week Low	$0.2975
Market Capitalization	$59.94M
EPS (Annual)	-$0.1211
Price to Book	10.02
Revenue Per Employee	$1.21M

Feed

News

Sentiment

Earnings

Fundamentals

Info

HRTX Fundamentals